$84.02
4.125.16%
最終更新: Oct 19, 10:25 AM
$82.29
2.392.99%
Benzinga
Benzinga
Benzinga
月曜日, 10 19
Benzinga
© 2026 Benzinga | All Rights Reserved
Spyre Therapeutics (SYRE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.74 | $-0.66 | $-0.74 | $-0.72 |
| Actual | $-0.36 | $-0.74 | $-0.70 | $-0.15 |
| Surprise | +51.3% | -12.1% | +5.41% | +79.2% |
| Revenue | ||||
| Estimate | — | — | $111110 | — |
| Actual | $0 | $0 | $0 | — |
| Surprise | — | — | -100.0% | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.82 | $-0.85 | $-0.88 | $-0.85 |
| Revenue | ||||
| Consensus | — | — | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.36 | $-0.74 | 51.3 % |
| Q1 | May 5, 2026 | $-0.74 | $-0.66 | -12.1 % |
| Q4 | Feb 19, 2026 | $-0.70 | $-0.74 | 5.41 % |
| Q3 | Nov 4, 2025 | $-0.15 | $-0.72 | 79.2 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q4 | Feb 19, 2026 | $0 | $111.11K | -100.0 % |
| Q1 | May 8, 2025 | $0 | $4.00M | -100.0 % |
| Q4 | Feb 27, 2025 | $0 | $2.33M | -100.0 % |
| Q4 | Feb 29, 2024 | $0 | $220.00K | -100.0 % |